Home Dialysis Services: Peritoneal and Home Hemodialysis Options

Home dialysis encompasses two distinct renal replacement therapy modalities — peritoneal dialysis (PD) and home hemodialysis (HHD) — both of which allow patients with end-stage renal disease (ESRD) or advanced chronic kidney disease (CKD Stage 5) to receive life-sustaining treatment outside a clinical facility. The Centers for Medicare & Medicaid Services (CMS) regulates both modalities under the ESRD Prospective Payment System (PPS), established under 42 CFR Part 494. This page covers the mechanical structure, regulatory framework, classification boundaries, clinical tradeoffs, and operational steps associated with each home dialysis modality.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps (Non-Advisory)
• Reference Table or Matrix

Definition and Scope

Home dialysis refers to kidney replacement therapy administered in a patient's residence rather than a dialysis center. The two primary forms are peritoneal dialysis, which uses the peritoneal membrane as a filtration surface, and home hemodialysis, which filters blood through an external dialyzer machine. Both modalities address the same clinical endpoint — removing uremic toxins and excess fluid when the kidneys cannot perform these functions — but differ substantially in mechanism, equipment, training burden, and scheduling.

The ESRD Networks, administered through contracts with CMS under 42 CFR Part 405 Subpart U, monitor outcomes and quality metrics for both modalities across 18 geographic networks covering all U.S. states and territories. The home-care-for-chronic-conditions context is essential for understanding how dialysis fits into the broader continuum of disease management for kidney failure patients. The National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) publish clinical guidelines that inform, but do not replace, CMS coverage standards.

Scope of coverage under Medicare Part B and the ESRD PPS is defined primarily by 42 CFR §413.230, which establishes the base rate for dialysis treatments and includes composite-rate bundling for most supplies, equipment, and medications related to the modality. As of the 2024 payment year, CMS set the ESRD PPS base rate at $271.02 per treatment (CMS ESRD PPS 2024 Final Rule).

Core Mechanics or Structure

Peritoneal Dialysis (PD)

Peritoneal dialysis uses the peritoneal membrane — the tissue lining the abdominal cavity — as a semi-permeable filter. A surgically placed catheter (most commonly a Tenckhoff catheter) delivers dialysate fluid into the peritoneal space. Solutes and excess fluid diffuse across the membrane into the dialysate over a defined dwell time, after which the fluid is drained. This fill-dwell-drain cycle is called an exchange.

PD exists in two primary technical formats:

• Continuous Ambulatory Peritoneal Dialysis (CAPD): Manual exchanges, typically 4 per day, each lasting 4–6 hours. No machine required during exchanges.
• Automated Peritoneal Dialysis (APD): A cycler machine performs exchanges overnight, usually over 8–10 hours. APD is also called continuous cycling peritoneal dialysis (CCPD).

Home Hemodialysis (HHD)

Home hemodialysis replicates the mechanism used in center-based dialysis: blood is drawn from the patient via a vascular access (arteriovenous fistula, graft, or tunneled catheter), passed through a dialyzer (artificial kidney) where diffusion and ultrafiltration occur across a semipermeable membrane, and returned to the patient. The key operational difference is the frequency and session duration available at home.

HHD machines approved by the U.S. Food and Drug Administration (FDA) for home use include the NxStage System One and the Fresenius 2008K@home, both cleared under 21 CFR Part 892 and subject to FDA 510(k) premarket notification requirements. Home medical equipment and DME standards govern how such devices are classified, maintained, and billed under the ESRD bundled payment.

Causal Relationships or Drivers

Patient selection for home dialysis is driven by a combination of clinical, social, and structural factors:

Clinical factors: Residual renal function, cardiovascular stability, peritoneal membrane transport characteristics (classified by the peritoneal equilibration test, or PET, into high, high-average, low-average, and low transport categories), and vascular access quality all shape which modality is feasible or preferred. High-transport PD patients typically require shorter dwell times or APD to avoid reabsorption of glucose and inadequate ultrafiltration.

Regulatory drivers: The CMS ESRD Treatment Choices (ETC) Model, finalized in the 2020 ESRD PPS Final Rule and operational from January 1, 2021, financially incentivizes dialysis facilities and nephrologists to increase home dialysis rates through payment adjustments of up to 3% upward for high performers and up to 3% downward for underperformers (CMS ETC Model).

Structural barriers: Access to trained support (a care partner for HHD is frequently required but not universally mandated), home physical space sufficient to store supplies (PD patients typically require dedicated storage for 30-day supply deliveries weighing 40–60 pounds per shipment), and reliable water quality for HHD (municipal water must be further purified through reverse osmosis or deionization systems).

The relationship between home dialysis frequency and clinical outcomes is documented in the FHN (Frequent Hemodialysis Network) Trial, a randomized controlled study published in the New England Journal of Medicine (2010), which found that 6-times-weekly HHD was associated with reductions in left ventricular mass and improved physical health scores compared to conventional 3-times-weekly center dialysis.

Classification Boundaries

Home dialysis modalities are classified along three primary axes: mechanism, automation level, and frequency protocol.

Nocturnal Home Hemodialysis (NHHD) is a distinct sub-classification in which extended sessions (6–8 hours) occur during sleep, 3–6 nights per week. Urea clearance (Kt/V) targets differ between modalities: conventional HHD follows the same minimum Kt/V ≥ 1.2 per session standard as center HD (per KDOQI Clinical Practice Guidelines), while frequent HHD regimens use a weekly Kt/V threshold rather than a per-session metric.

For PD, the National Kidney Foundation KDOQI 2006 Update recommends a minimum weekly Kt/V of 1.7 for PD patients. Patients who retain significant residual renal function may meet adequacy targets with fewer exchanges or shorter machine cycles.

Skilled nursing at home support may be involved during PD catheter exit-site care or HHD access management, depending on the patient's self-care capacity and plan of care requirements.

Tradeoffs and Tensions

Peritoneal Dialysis

• Advantage: Hemodynamic stability; no vascular access; continuous low-level clearance; no machine for CAPD.
• Tension: Risk of peritonitis — the primary PD complication — with rates benchmarked by the International Society for Peritoneal Dialysis (ISPD) at a target of less than 0.5 episodes per patient-year (ISPD Guidelines 2022). Membrane failure over time (encapsulating peritoneal sclerosis risk with long-term use), and glucose-based dialysate contributing to metabolic complications are persistent concerns.

Home Hemodialysis

• Advantage: Greater solute clearance flexibility; potential cardiovascular benefit from more frequent sessions; no peritoneal membrane exposure.
• Tension: High training burden (typically 3–6 weeks of in-center training); dependence on functioning vascular access; water treatment system maintenance; machine alarm management during nocturnal sessions poses safety monitoring challenges. A care partner requirement, while not universally mandated by CMS, is recommended by most training programs for safety during needle cannulation and alarm response.

System-Level Tension: The 2019 Executive Order on Advancing American Kidney Health directed HHS to set a goal of 80% of new ESRD patients receiving home dialysis or transplant by 2025 (HHS Advancing American Kidney Health), creating structural pressure on dialysis providers to expand home programs even where patient or infrastructure suitability is constrained.

Common Misconceptions

Misconception 1: PD is always continuous and HHD is always intermittent.
Correction: APD (automated PD) is performed cyclically overnight and is not technically continuous during the day if no daytime exchange is prescribed. Nocturnal HHD, conversely, involves extended duration that approximates continuous renal function more closely than standard center HD.

Misconception 2: Home dialysis requires a full-time caregiver.
Correction: Many PD patients and a portion of HHD patients perform therapy independently. Solo HHD programs exist at several large nephrology centers and use enhanced monitoring technologies. CMS does not mandate a care partner as a coverage condition, though individual training programs may establish their own criteria.

Misconception 3: Home dialysis is not reimbursed differently from center dialysis.
Correction: Under the ESRD PPS, the same base rate applies regardless of setting, but home dialysis patients may qualify for additional adjustments. The Home Dialysis Training Add-On, authorized under the 21st Century Cures Act (Pub. L. 114-255), provides an additional payment per training session to facilities that train patients for home modalities.

Misconception 4: Peritoneal dialysis is only for patients who fear needles.
Correction: Clinical suitability for PD is determined by peritoneal membrane characteristics, abdominal surgical history, and residual renal function — not patient preference alone. Prior abdominal surgeries (appendectomy, hernia repair) do not automatically disqualify a patient but require evaluation for adhesions.

Misconception 5: HHD machines are the same as center dialysis machines.
Correction: FDA-cleared home hemodialysis machines are specifically designed for operation by non-clinical users in residential settings. They incorporate simplified interfaces, automated priming sequences, and safety shutoffs not present in all center-based machines. The regulatory clearance pathway (510(k) under 21 CFR Part 892) requires demonstrated safety for lay use.

Checklist or Steps (Non-Advisory)

The following sequence reflects the operational phases involved in initiating home dialysis, as described in CMS Conditions for Coverage (42 CFR §494.100) and KDOQI training guidance. This is a structural reference, not clinical instruction.

Phase 1 — Candidacy Evaluation
- [ ] Nephrology evaluation of ESRD diagnosis and GFR staging
- [ ] Peritoneal equilibration test (PET) if PD is under consideration
- [ ] Vascular access assessment if HHD is under consideration
- [ ] Home environment assessment: space, water supply, electrical capacity, supply storage
- [ ] Social support and care partner availability documented

Phase 2 — Modality Selection and Planning
- [ ] Modality-specific education provided (CMS §494.100 mandates patient education on all treatment options)
- [ ] Training facility identified and enrolled under ESRD certification
- [ ] Plan of care established with nephrologist and home dialysis nurse
- [ ] DME and supply vendor coordinated for delivery schedule

Phase 3 — Training
- [ ] PD training: typically 5–10 days for CAPD; 7–14 days for APD
- [ ] HHD training: typically 3–6 weeks including vascular access cannulation
- [ ] Emergency protocols reviewed: disconnection, alarm response, peritonitis recognition
- [ ] Machine operation competency verified by dialysis nurse

Phase 4 — Initiation and Monitoring
- [ ] First home treatment completed with facility backup contact established
- [ ] Monthly laboratory adequacy testing (Kt/V, BUN, phosphorus, albumin)
- [ ] Quarterly home visit or telehealth review per telehealth in home care protocols
- [ ] Exit-site or access site monitoring per infection control in home care standards
- [ ] Adverse event reporting to ESRD Network per 42 CFR §494.180

Reference Table or Matrix

Comparison of Major Home Dialysis Modalities

References

• Centers for Medicare & Medicaid Services — ESRD Prospective Payment System
• CMS — ESRD Treatment Choices (ETC) Model
• CMS — Conditions for Coverage for ESRD Facilities, 42 CFR Part 494
• National Kidney Foundation — KDOQI Clinical Practice Guidelines
• International Society for Peritoneal Dialysis — 2022 Guidelines on Peritonitis
• [U.S. Food